A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.

Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early clinical studies have reported anti-tumour activity. In a phase II study 32 patients with previously treated advanced breast cancer were given Lonidamine in a daily divided oral dose of 600 mg. Of 28 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansi, J. L., de Graeff, A., Newell, D. R., Glaholm, J., Button, D., Leach, M. O., Payne, G., Smith, I. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977661/
https://www.ncbi.nlm.nih.gov/pubmed/1911204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977661/
https://www.ncbi.nlm.nih.gov/pubmed/1911204

Ejemplares similares